Model Systems
We have developed over 100 patient derived cultures from breast tumors of stages 0-IV (N=60) (JL-BTLs), non-tumor adjacent tissues (N= 54) (JL-NTALs) and breast reduction mammoplasties (N= 40) (JL-BRLs) using a novel tissue engineering system. These patient derived cultures are from women and men of different ancestries that include Afro-Caribbean, African American, Hispanic and Non Hispanic White. Our breast tissue engineering system and some of these cultures have been published (see below).
Latimer, J.J., Nazir, T., Flowers, L.C., Forlenza, M.J., Beaudry-Rodgers, Kelly, C.M., Conte, J.A., Shestak, K., Kanbour-Shakir, A., and Grant, S.G. (2003). Unique tissue-specific level of DNA nucleotide excision repair in primary human mammary epithelial cultures. Experimental Cell Res 291: 111-121. doi: 10.1016/s0014-4827(03)00368-9 (Multiple JL-BRLs)
Latimer, J.J., Rubinstein, W.S., Johnson, J.M., Kanbour-Shakir, A., Vogel, V.G., and Grant, S.G. (2005). Haploinsufficiency for BRCA1 is associated with normal levels of DNA nucleotide excision repair in breast tissue and blood lymphocytes. BMC Medical Genetics 6: 26 (published online 06-14-05). doi: 10.1186/1471-2350-6-26 (Multiple JL-BRLs)
Latimer, J.J., Johnson, J.M., Miles, T.D., Dimsdale, J.M., Edwards, R.P., Kelley, J.L., and Grant, S.G. (2008). Cell-type-specific level of DNA nucleotide excision repair in primary human mammary and ovarian epithelial cell cultures. Cell and Tissue Research 333: 461–467 (published online 6-25-08). doi: 10.1007/s00441-008-0645-1 (Multiple JL-BRLs)
Sajithlal, G.S., Rothermund, K., Zhang, F., Dabbs, D.J., Latimer, J.J., Grant, S.G., and Prochownik, E.V. (2010). Permanently blocked stem cells derived from breast cancer cell lines. Stem Cells 28: 1008–1018 (published online 4-7-10). doi: 10.1002/stem.424 (JL-BTL-12)
Latimer, J.J., Johnson, J.M., Kelly, C.M., Miles, T.D., Beaudry-Rodgers, K.A., Lalanne, N.A., Vogel, V.G., Kanbour-Shakir, A., Kelley, J.L., Johnson, R.J., and Grant, S.G. (2010). Nucleotide excision repair deficiency is intrinsic in sporadic stage I breast cancer. Proceedings of the National Academy of Sciences (U.S.A.) 50: 21725–21730 (published online 11-30-10). doi: 10.1073/pnas.0914772107 (JL-BTL-4, JL-BTL-8, JL-BTL-33)
Visus, C., Ito, D., Dhir, R., Szczepanski M.J., Chang, Y. J., Latimer, J.J., Grant, S.G., and DeLeo, A.B. (2011). Identification of hydroxysteroid (17) dehydrogenase type 12 (HSD17B12) as a CD8+ T-cell-defined human tumor antigen of human carcinomas. Cancer Immunology Immunotherapy 60: 919–929 (published online 3-16-11). doi: 10.1007/s00262-011-1001-y (JL-BRL-6)
Wend, P., Runke, S., Wend, K., Anchondo, B., Yesayan, M., Jardan, M., Hardie, N., Loddenkemper, C., Ulasov, I., Lesniak, M.S., Wolsky, R., Bentolila, L.A., Grant, S.G., Elashoof, D., Lehr, S., Latimer, J.J., Bose, S., Sattar, H., Krum, S.A., and Miranda-Carboni, G.A. (2013). WNT10B/- catenin signaling induces HMGA2 and proliferation in metastatic triple-negative breast cancer. EMBO Molecular Medicine 5: 1–16 (published online 1-11-13). doi: 10.1002/emmm.201201320 (JL-BTL-10)
Dodda, B., Corry, D., Bondi, C.D., Hasan, M., Clafshenkel, W.P., Gallagher, K.M., Kotlarczyk, M.P., Sethi,S., Buszko, E., Latimer, J.J., Cline, J.M, Witt-Enderby, P.A. and Davis, V.L. (2019). Co-administering Melatonin with an Estradiol-Progesterone Menopausal Hormone Therapy Represses Mammary Cancer Development in a Mouse Model of HER2-positive Breast Cancer, Frontiers in Oncology 9: 525 doi: 10.3389/fonc.2019.00525